Trial Profile
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 08 Dec 2015 Results (n=49) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 17 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 05 Feb 2013 Planned number of patients changed from 42 to 66 as reported by ClinicalTrials.gov.